Fractional Cmo
Current
Nov 2024 - Present
AeroLeads people directory · profile
Mark Versavel Email & Phone Number
President at vZenium LLC, Fractional CMO at Consano Bio
at
Consano Bio
1 work email found
@alzheon.com
6 phones found area 781 and 401
LinkedIn matched
✓ Verified May 2026
4 data sources
Profile completeness 100%
Current company
Role
President at vZenium LLC, Fractional CMO at Consano Bio
Location
Arlington, Massachusetts, United States
Who is Mark Versavel? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Mark Versavel is listed as President at vZenium LLC, Fractional CMO at Consano Bio at Consano Bio, based in Arlington, Massachusetts, United States. AeroLeads shows a work email signal at alzheon.com, phone signal with area code 781, 401, and a matched LinkedIn profile for Mark Versavel.
Mark Versavel previously worked as Fractional CMO at Consano Bio and President at Vzenium Llc. Mark Versavel holds Mba, Business Administration from University Of Michigan - Stephen M. Ross School Of Business.
Company email context
Email format at Consano Bio
This section adds company-level context without repeating Mark Versavel's masked contact details.
{first}.{last}@alzheon.com
86% confidence
AeroLeads found 1 current-domain work email signal for Mark Versavel. Compare company email patterns before reaching out.
Profile bio
About Mark Versavel
Clinical pharma consultant as President of vZenium LLC. Currently appointed as clinical consultant for Afasci, Alzheon, Bial, Biodol, Noema and Vigil Neuro. Former CMO and Senior VP at Eliem Therapeutics. Scientific advisory board member at Confo. Providing clinical development support to biotech and pharmaceutical companies, building on >30 years experience in clinical development and medical affairs in multiple CNS indications including stroke, neuropathic pain, multiple sclerosis, Parkinson's, restless legs, Huntington's, Alzheimer's, epilepsy, autism, schizophrenia, bipolar disorder and depression. Track record of achievements through multi-disciplinary team-leadership with a cooperative leadership style, motivating teams to top performance and persisting though difficult periods, always looking for solutions and creative ways to move the project forward. Strong analytical and judgment skills and capability to make decisions in the face of uncertainty. Flexibility and capacity to learn and succeed in new situations and cultures, with extensive international experience (Belgium, Netherlands, Germany, France, USA).•Bringing Alzheon's drug ALZ-801 to Phase 2-3 in Alzheimer's Disease.•Completed 2 Phase 2 trials with Z160 in neuropathic pain at Zalicus, and demonstrated efficacy of Z944 in laser evoked pain model.•Created pharmaco-EEG and neuropsychological test unit, performed validation studies that led to PhD thesis on the use of psychometric tests in healthy volunteers.•Clinical pharmacology lead for nimodipine (Nimotop®), ipsapirone CR, BAYx 3702, metrifonate•Clinical development for ziprasidone (Geodon®) in schizophrenia and bipolar disorder, pregabalin (Lyrica®) in epilepsy and neuropathic pain, sumanirole in Parkinson’s disease and Restless Legs Syndrome, AMPA antagonist in stroke•Medical Affairs and Phase IV experience with eslicarbazepine acetate (Aptiom®) in epilepsy, eszopiclone (Lunesta®) in insomnia, Lyrica® and gabapentin (Neurontin®) in neuropathic pain and epilepsy, Rebif® and Betaferon® / Betaseron® in MS,
Listed skills include Clinical Development, Clinical Trials, Neurology, Pharmaceutical Industry, and 29 others.
Current workplace
Mark Versavel's current company
Company context helps verify the profile and gives searchers a useful next step.
23 roles
Mark Versavel work experience
A career timeline built from the work history available for this profile.
President
Current
Vzenium Llc
Neurologic and psychiatric diseases are amongst the leading causes of disability. Neuroscience is making rapid progress and new drugs are being discovered that promise help for patients, doctors and society.vZenium is a life science consulting firm created to assist teams in small and large pharmaceutical companies to manage the development of new.
Mar 2014 - Present
Mar 2023 - Oct 2023
Interim Cmo
Jan 2022 - Oct 2023
Senior Vp Clinical
Mar 2021 - Jan 2022
Chief Medical Officer
Developing proprietary treatments for neurodegeneraative disorders such as Alzheimer's disease, and neuropathic pain using botanicals
Feb 2018 - Jan 2021
Co Founder
Viepage
Viepage LLC is developing CalendU, a calendar app for better organization of multiple life and work activities. Today Viepage has 5 LOI's signed, 2 new investors on board and it has a demo ready to show, while it is still looking for funds to get the product finished and launched. Find more information on www.calendutheapp.com
Jul 2014 - Dec 2020
Chief Medical Officer
Cavion, Inc.
Developing CX-8998 in essentiel tremor and epilepsy.
Mar 2019 - Aug 2019
Principal
akta Pharmaceutical DevelopmentTM (aktaPD) is a progressive international company engaged in the design, development, and commercialization of treatments for diseases. The company is comprised of a consortium of experts with broad expertise in all development phases of multiple therapeutic areas. aktaPD has secured its place as the pharmaceutical.
Mar 2014 - Nov 2015
Chief Medical Officer
Clinical development of ALZ-801 as potential first in class disease modifying agent in Alzheimer's disease.
Dec 2013 - Sep 2015
Vp Clinical Research
Zalicus Incorporated
Leading clinical development and operations for N-type Ca channel antagonist (2 Phase II studies starting) and T-type Ca channel antagonist (currently in Phase I)
Sep 2012 - Nov 2013
Vice President Cns, Clinical Development And Medical Affairs
Leading CNS clinical development Phases I-IV, including medical affairs activities. Phase III-IV development of eslicarbazepine acetate in epilepsy. Early development in pai n and schizophrenia. Sunovion was previously known as Sepracor.
Jul 2009 - Jun 2012
Executive Medical Director Clinical Research Cns
Medical lead for NDA submission, initiation of monotherapy studies and publication activities with eslicarbazepine acetate in epilepsy.
Feb 2008 - Jul 2009
Chairman Of The Board Of Directors
Led the Board in providing oversight to the school's function. Supported creation of Middle School, improved Board organization through committees, increased focus on fundraising and performance evaluation.
Sep 2004 - Jun 2009
Senior Director Clinical Development Neuroscience
Global Clinical Lead for ziprasidone R&D studies in bipolar disorder and schizophrenia
Aug 1999 - Feb 2008
Core Clinician
Schering Ag
Lead Phase II development of AMPA antagonist in stroke.
Oct 1995 - Jul 1999
Medical Director Phase I-Ii
Pharmacon Research
Leading Phase I-II studies in Germany / Berlin
Mar 1995 - Sep 1995
Sep 1994 - Feb 1995
Projektleiter Klinische Pharmakologie
Planned and conducted Phase I studies with nimodipine, ipsapirone, metrifonate. Established and validated pharmaco EEG and computerized cognitive testing in the Phase I unit.
Jan 1989 - Aug 1994
Assistent Neurology
Universitaetsklinikum Grosshadern, Muenchen
In-patient medical care with focus on epilepsy and Parkinson's disease.
Jan 1988 - Dec 1988
Scientific Assistant
Universiteit Leuven, Belgium
Investigated neurophysiology of curvature processing in cat visual cortex
Jan 1987 - Dec 1987
Assistent Neurosurgery
Slotervaartziekenhuis Amsterdam
Assisting neurosurgical procedures with a focus on spinal surgery. Pre-and postoperative patient care.
Jun 1986 - Dec 1986
Assistent Surgery / Neurosurgery / Neurology
Universitair Ziekenhuis Antwerpen
Assisting neurosurgical procedures. Pre-and postoperative patient care including pain clinic.
Sep 1983 - May 1986
5 education records
Mark Versavel education
Mba, Business Administration
University Of Michigan - Stephen M. Ross School Of Business
Dr Med, Clinical Pharmacology
Humboldt-Universität Zu Berlin
Md, Medicine
University Of Antwerp
High School Graduation, Latin And Mathematics
Onze-Lieve-Vrouw-Van-Lourdescollege Edegem
Education record
Basisschool Abraham Hans, Kontich
FAQ
Frequently asked questions about Mark Versavel
Quick answers generated from the profile data available on this page.
What company does Mark Versavel work for?
Mark Versavel works for Consano Bio.
What is Mark Versavel's role at Consano Bio?
Mark Versavel is listed as President at vZenium LLC, Fractional CMO at Consano Bio at Consano Bio.
What is Mark Versavel's email address?
AeroLeads has found 1 work email signal at @alzheon.com for Mark Versavel at Consano Bio.
What is Mark Versavel's phone number?
AeroLeads has found 6 phone signal(s) with area code 781, 401 for Mark Versavel at Consano Bio.
Where is Mark Versavel based?
Mark Versavel is based in Arlington, Massachusetts, United States while working with Consano Bio.
What companies has Mark Versavel worked for?
Mark Versavel has worked for Consano Bio, Vzenium Llc, Eliem Therapeutics, Neurobo Pharmaceuticals, Inc., and Viepage.
How can I contact Mark Versavel?
You can use AeroLeads to view verified contact signals for Mark Versavel at Consano Bio, including work email, phone, and LinkedIn data when available.
What schools did Mark Versavel attend?
Mark Versavel holds Mba, Business Administration from University Of Michigan - Stephen M. Ross School Of Business.
What skills is Mark Versavel known for?
Mark Versavel is listed with skills including Clinical Development, Clinical Trials, Neurology, Pharmaceutical Industry, Clinical Research, Biotechnology, Neuroscience, and Drug Development.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial